M-CERSI Lecture: Zika Virus Vaccines and Therapeutics
Thursday, April 13, 2017
3:00 p.m.-4:00 p.m.
Shari Solomon, ORSI
Monica McArthur, M.D., Ph.D.
University of Maryland School of Medicine
Zika Virus Vaccines and Therapeutics
You are invited to attend the next lecture of FDA’s 2017 CERSI Lecture Series on Thursday, April 13, 2017, at 3:00 – 4:00 pm EST via webinar. University of Maryland CERSI is the host and their guest speaker is Monica McArthur, MD, PhD, who will present on: "Zika Virus Vaccines and Therapeutics.” Additional information is provided below and also at: https://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm550152.htm (fyi-having technical difficulties with display of Monica’s photo – hope to have it resolved soon). Please advertise this lecture to others at your University. Thank you!
About the Speaker
Dr. McArthur's research interests include the interactions between pathogens and the human immune system. She is particularly interested in T cell responses against infectious agents affecting children in the developing world. Currently, Dr. McArthur is leading the Zika vaccine clinical trial at the University of Maryland CVD.
About the Presentation
Zika virus is a rapidly emerging infectious disease of great public health importance. Although infections are frequently asymptomatic or mildly symptomatic, associations with severe neurologic complications in infants born to mothers infected with Zika virus during pregnancy as well as neurologic complications in adults (e.g., Guillan Barre Syndrome) have made Zika virus a high priority pathogen. There are currently no licensed vaccines or therapeutics against Zika virus; however, there are numerous vaccine candidates currently in development. The anti-Zika virus vaccine candidates currently in the pipeline as well as ongoing efforts to identify therapeutics effective against this pathogen will be discussed.
Remote Access Information
Remote Access link for the lecture is at: https://collaboration.fda.gov/cersilectures/
FOR QUESTIONS: Contact Amal Manseur at Amal.Manseur@fda.hhs.gov.